Tuberculosis Testing 2012: An Online Tutorial Using IGRA

Tuberculosis

INSTRUCTIONS

After completing the demographic questionnaire and the CME posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you very much for your participation.


CE Information

Tuberculosis Testing: An Online Tutorial Using IGRA

Release date: June 11, 2015
Expiration date: June 30, 2017

Faculty
Dana C Drew-Nord, PhD, APRN, BC
Assistant Clinical Professor
University of California, San Francisco
School of Nursing
Nurse Practitioner/Administrator
Premier COMP Medical Group, Inc
Pleasanton, California

About the Program
In the United States, the rate and number of tuberculosis (TB) cases has been steadily declining since 1993. While this is encouraging, more effort is needed to control this disease and appropriate screening is at the center of that fight. Two types of TB screening tests are available in the United States: tuberculin skin tests (TSTs) and interferon gamma release assays (IGRAs). IGRAs are faster, more accurate, and less prone to misinterpretation than TSTs, but require careful technique when collecting and preparing patient samples for testing. This online tutorial will provide practical information that will help nurses, technicians, and laboratory staff obtain and process IGRA specimens consistent with the approved labeling of the tests to assure high quality control and avoid unnecessary treatment referrals.

Target Audience
This activity is intended for nurses and clinical laboratory staff involved in the collection and processing of tuberculosis screening tests.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Differentiate between latent and active TB infection
  • Discuss the differences between TSTs and IGRAs in TB surveillance and diagnosis
  • Explain the possible consequences of false-positive and false-negative TB tests and what it would mean for misdiagnosed individuals and public health
  • Describe the steps involved in preparing a patient sample for IGRA testing
  • Identify and correct common sources of error in IGRA sample processing

Accreditation and Credit Designation Statements

Nurses
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 0.75 contact hours (0.075 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Clinical Laboratory Staff
The Institute for Medical and Nursing Education, Inc is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program (Provider 524). This program is approved for 0.5 contact hours

Disclaimer
This activity is designed for healthcare providers for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

Disclosures
In compliance with the ACCME, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, continuing education provider staff, and educational partner staff) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical agents and medical devices.

In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content. The following disclosures have been made:

Faculty
Dana C Drew-Nord, PhD, APRN, BC
Speaker's Bureau: Cellestis

Dr Drew-Nord has disclosed that she does not anticipate discussing off-label or investigational uses of any therapies, products, or devices.

IMNE Staff
Amy Carbonara
Director, Program Development
IMNE
Ms Carbonara has nothing to disclose.

Katie Fidanza
Program Manager
IMNE
Ms Fidanza has nothing to disclose.

Angela McIntosh, PhD
Scientific Director
IMNE
Dr McIntosh has nothing to disclose.

Marge Tamas
Editorial Manager
IMNE
Ms Tamas has nothing to disclose.

Steve Weinman, RN
Executive Director
IMNE
Mr Weinman has nothing to disclose.

Darylin Paul, RN, MS, CS, APRN-BC, CCRN
CE Reviewer
IMNE
Ms. Paul has nothing to disclose

Commercial Support Acknowledgment
Supported by an educational grant from QIAGEN Inc..

Method of Participation

To obtain CME/CE credit, each participant should:

  1. View the content presented
  2. Answer all questions posed throughout the activity
  3. Complete and submit the CME demographic and evaluation form
  4. Print the online CME/CE certificate

This activity should take approximately 0.75 hours to complete.

Minimum System Requirements
The following system requirements are recommended for the best presentation viewing experience:

Windows Vista, or Macintosh OS X
Display resolution of 800 x 600 pixels or greater
Windows-compatible sound card
Microsoft Internet Explorer 8.0 SP1.
Windows Media Player 9.0
Broadband Internet connection (256 Kbps & above)

If you have any questions about viewing the webcast please contact Steve Weinman at steve.weinman@imne.com

 I have read and understand the CME Information indexed above.

Pre-activity Survey - must be completed before viewing videos

In your current practice, how often do you use tuberculosis surveillance methods (eg, acid fast bacilli stain, tuberculin skin tests or interferon gamma release assays) to screen patients for possible infection?
A: Daily
B: Weekly
C: Monthly
D: Annually
Which TB screening method is used most often at your institution?
A: Acid fast bacilli stain
B: Tuberculin skin test
C: Interferon gamma release assay (T. Spot, QuantiFERON-TB Gold)
D: Not sure
E: All 3 methods are used equally
What factors determine which test is selected to screen for TB infection? Select all that apply.
A: Prescriber preference
B: Test availability
C: Cost
D: Time to required to obtain results
E: Staff training
How confident are you that you are currently performing TB surveillance appropriately?
A: Avoid TB screening completely
B: Not at all confident
C: Somewhat confident
D: Highly confident

CME/CE Posttest and Evaluation

    •  
    • CME/CE credit is offered upon successful completion of the posttest with a minimum passing score of 80%. The evaluation portion of this activity will be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • After completing the posttest and CME/CE evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.
    •  
    • Contact IMNE for questions regarding CME Credits: steve.weinman@imne.com.
    •  
    •  
    • You must be signed in to WebBasedCME.com in order to participate and receive CME credit. New to WebBasedCME.com? Click here to register.